Stephen Liu
MD
Associate Professor of Medicine, Director of Thoracic Oncology and Director of Developmental Therapeutics
Georgetown Lombardi Comprehensive Cancer Center
Feb 14, 2023
Episode
145
Soundcloud
Share
KRAS – specifically, advanced NSCLC with a KRAS G12C mutation, has emerged as a unique area of research for a select group of oncologists. To help us understand what these mutations mean, Lung Cancer Considered host Dr. Stephen Liu interviewed two leading thoracic medical oncologists in the field: Dr. Melissa Johnson, the Program Director of Lung Cancer Research at the Sarah Cannon Research Institute and Dr. Ferdinandos Skoulidis, an Associate Professor at the University of Texas MD Anderson Cancer Center.
Guest
Melissa Johnson
MD
Program Director of Lung Cancer Research
Sarah Cannon Research Institute
Ferdinandos Skoulidis
MD, PhD
Associate Professor, Department of Thoracic and Head and Neck Medical Oncology
University of Texas MD Anderson Cancer Center
